Business

European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai

The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine."

adminadmin
Jul 26, 2024 - 20:00
 0  4
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine."
Read More

Tags:

Previous Article

Paris Olympics is the latest test of whether sports can win subscribers for NBC'...

Next Article

LVMH CEO Bernard Arnault says Olympics sponsorship honors the spirit of France

admin
admin

Related Posts

Stocks making the biggest moves premarket: Hershey, Meta Platforms, Arm Holdings, Shake Shack and more

Stocks making the biggest moves premarket: Hershey, Met...

admin Aug 1, 2024  0  5

Jeremy Siegel backs off on calls for the Fed to do an emergency interest rate cut

Jeremy Siegel backs off on calls for the Fed to do an e...

admin Aug 9, 2024  0  8

Sports streaming venture Venu priced at $42.99 a month

Sports streaming venture Venu priced at $42.99 a month

admin Aug 1, 2024  0  40